Loading stock…

Maze Therapeutics, Inc. (MAZE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Maze Therapeutics, Inc.

MAZEMarket cap $1.44BPrice $25.9

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops precision medicines by targeting genetic modifiers that determine why some people resist disease despite high-risk mutations. Its pipeline includes treatments for kidney disease and metabolic disorders, betting that human genetics itself reveals nature's best drug targets.

In Bastion Portfolios?

52W Return-7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)na–

Rev CAGR (3y)na–

Rev CAGR (5y)na–

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-728%1

Net Income Margin-668%1

Free Cash Flow Margin-534%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-37%1

ROA-32%1

Earnings Stability22

GEAR+VERY WEAK1

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV3.25

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-7.4%1

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return-20%2

YTD return-38%1

Mid term

Price vs 52wHigh48%1

1 year return-10%3

Long term

3 year return+62%6

5 year return+62%6

Risk Shield

Price Risk

Beta1.04

Volatility70%1

Free Cash Flow

Free Cash Flow Margin-534%1

Free Cash Flow Yield-7.4%1

Quality

ROCE-37%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-20%2

YTD return-38%1

MID & LONG-TERM▾SCORE

% of 52-week high48%1

1-year return-10%3

3-year return+62%6

5-year return+62%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Average long-term results. Multi-year returns are middling (+62% over three years and +62% over five), roughly average for the market.

WEAKNESSES

It's down 10% over the past year, now 52% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-20%) and so far this year (-38%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Maze Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return-20%2

YTD return-38%1

MID & LONG-TERM▾SCORE

% of 52-week high48%1

1-year return-10%3

3-year return+62%6

5-year return+62%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+5%).

WATCH

Average long-term results. Multi-year returns are middling (+62% over three years and +62% over five), roughly average for the market.

WEAKNESSES

It's down 10% over the past year, now 52% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-20%) and so far this year (-38%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Maze Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community